Filtered By:
Cancer: Ovarian Cancer
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 759 results found since Jan 2013.
Frizzled-3 suppression overcomes multidrug chemoresistance by Wnt/ β-catenin signaling pathway inhibition in hepatocellular carcinoma cells
This study aimed to identify a potential target in HCC chemotherapy. The FZD3 expression variant in HCC cell lines was detected by RT-qPCR and western blotting. The FZD3 expression in the early recurrent HCC group (RE group) and the non-early recurrent HCC group (non-RE group) was measured by RT-qPCR. Then, the 50% inhibitory concentrations (IC50) in HCC cell lines were studied by MTT assay. TOP/FOP FLASH luciferase assay was performed to measure TCF-binding activities. We found that FZD3 was upregulated in three HCC cell lines, and the FZD3 expression was significantly higher in the RE group than in the non-RE group (P = ...
Source: Journal of Chemotherapy - February 27, 2023 Category: Cancer & Oncology Authors: Zifan Meng Qing Liu Yanfei Liu Yuanming Yang Changfeng Shao Shaoqiang Zhang Source Type: research
Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor
CONCLUSION: Our results illustrated that PARP inhibitors promote GCH1 expression via the JAK-STAT pathway. We also elucidated the potential relationship between GCH1 and the homologous recombination repair pathway and proposed a combination regimen of GCH1 suppression with PARP inhibitors in breast and ovarian cancers.PMID:36793373 | PMC:PMC9925261 | DOI:10.1155/2023/1453739
Source: Journal of Oncology - February 16, 2023 Category: Cancer & Oncology Authors: Siyuan Wang Yu Xia Pu Huang Cheng Xu Yiyu Qian Tian Fang Qinglei Gao Source Type: research
